CURRICULUM VITAE

Ronald Prussick, M.D., F.R.C.P.(C)

Board Certified in Dermatology

Washington Dermatology Center

6163 Executive Blvd

Rockville, MD. 20852

tel: (301) 984-3000

ACADEMIC APPOINTMENTS

Assistant Clinical Professor of Dermatology, George Washington University, Washington, D.C.

Staff Physician 1992-1995, Sunnybrook Medical Center, University of Toronto, Ontario

Clinical Instructor 1992-1995, Dermatology & Pharmacology, University of Toronto

EDUCATION

1991-92 Fellowship in Dermatological Immunology

National Cancer Institute, National Institutes of Health (NIH)

1991 Certification - American Board of Dermatology

1991 Fellow of the Royal College of Physicians & Surgeons

1988-91 Chief Resident, Dermatology

University of Toronto, Ontario

1990 Oxford Summer School on Wound Healing, England

1990 Contact Dermatitis, Stanford University & UC California San Francisco

1990 Psoriasis Education and Research Centre, Univ. of Toronto

1987-88 Comprehensive Internship in Internal Medicine, Univ. of Toronto

1983-87 McGill University School of Medicine, Montreal, Canada

1980-83 McGill University, B.Sc., Great Distinction, Major in Biology & Genetics

MEMBERSHIP AND COMMITTEES

2015-present Medical Scientific Advisory Board. Immunotec, Inc.

2014-present NPF: Washington, DC, Community Division Medical Member

2014-present NPF: Seal of Recognition- Expert Panel Member

2012-present Medical Board Member: National Psoriasis Foundation (NPF)

2012-present Psoriasis Expert Resource Group (PERG) member: AAD

2010-present PsoriasisNet Work group: American Academy of Dermatology (AAD)

2010-2011 Health Volunteers Overseas

2006-present National Psoriasis Foundation President’s Council

1997-2003 Chairman, Adverse Drug Reactions Committee, Suburban Hosp.

1997-2003 Pharmacy & Therapeutics Committee, Suburban Hosp.

1996-1998 Community Affairs Committee, MCMS

1995-present Montgomery County Medical Society (MCMS)

1995-present MedChi Maryland State Medical Society

1995-present American Society for Laser Medicine & Surgery

1993-present International Society for Dermatologic Surgery

1996-1998 Third Party Payer Committee, MCMS

1992-1995 Executive Council Toronto Dermatological Society

1991-present Fellow of the American Academy of Dermatology

1991-present Canadian Dermatology Association

1988-present The Ontario College of Physicians & Surgeons

1985-86 McGill Senate Committee on Disabled Students

1984-86 McGill Health Services Advisory Board

1984 Chairman, McGill Medical Blood Drive

1982-83 Committee on Faculty, McGill University

1982-83 Committee on Student Standing, McGill University

1982 Chairman, McGill University Blood Drive

EDITOR / REVIEWER - MEDICAL JOURNALS & INDUSTRY

2017- Psoriasis Advance Magazine- Medical Editor

2011-present Associate Journal Editor: Journal of Psoriasis and Psoriatic Arthritis (JPPA)

2004 Amgen - Dermatology Managed Care Panel, Washington, D.C.

2000 Alwyn, Inc. -Medical Advisor for TV spot: LupicareTM for Psoriasis

1993-present Journal of American Academy of Dermatology

TEACHING ACTIVITIES

2009 Allergan: JuvedermTM Physician Trainer

Medicis: DysportTM and RestylaneTM Physician Trainer

1995-present George Washington University, Medical Student/Dermatology Resident Teaching

1993-1995 University of Toronto Weekly Dermatology Teaching Clinics

Year III Medical Student Teaching: Group Leader, Hospital Clinics

Dermatology Residents: Group Leader, Journal Club

Examiner: Dermatology Residents’ Practice Examination

SKIN CARE DEVELOPMENT

2016- Creator of ELASENSE anti-aging skin care line with SynerG-4 sold worldwide.

Immunotec, Inc.

PUBLICATIONS

I. Peer Review Publications

Prussick R, Miele L. Nonalcoholic Fatty Liver Disease in Patients with Psoriasis: A

Consequence of Systemic Inflammatory Burden? Br J Dermatol. Accepted December 2017.

Prussick R, Wu JJ, Armstrong AW, Siegel MP, Van Voorhees AS. Psoriasis in Solid Organ

Transplant Patients: Best Practice Recommendations from the Medical Board of the National

Psoriasis Foundation. J Dermatol Treat. Published Oct 2017.

Dey AK, Joshi AA, Chaturvedi A, Lerman JB, Aberra TM, Rodante JA, Teague HL, Harrington

CL, Rivers JP, Chung JH, Kabbany MT, Natarajan B, Silverman JL, Ng Q, Sanda GE, Sorokin

AV, Baumer Y, Gerson E, Prussick RB, Ehrlich A, Green LJ, Lockshin BN, Ahlman MA,

Playford MP, Gelfand JM, Mehta NN. Association Between Skin and Aortic Vascular

Inflammation in Patients with Psoriasis. A Case-Cohort Study Using Positron Emission

Tomography/ Computed Tomography. JAMA Cardiol. 2017.Sep 1;2(9):1013-1018.

Armstrong AW, Siegel MP, Bagel J, Boh EE, Buell M, Cooper KD, Callis Duffin K, Eichenfield

LF, Garg A, Gelfand JM, Gottlieb AB, Koo JY, Korman NJ, Gerald G Krueger, Lebwohl MG,

Leonardi CL, Mandelin AM, Menter MA, Merola JF, Pariser DM, Prussick RB, Ryan C, Shah

KN, Weinberg JM, Williams MJ, Wu JJ, Yamauchi PS, Van Voorhees AS. From the Medical

Board of the National Psoriasis Foundation. Treatment Targets for Plaque Psoriasis. J Amer

Acad Dermatol. 2017;76(2):290-298.

Desai SR, Feldman S, Prussick R, Weiss S. Optimizing Adherence in Psoriasis: Pearls from the

Front Line. Practical Dermatology. 2017;14(1):42-43.

Prussick L, Jimenez E, Nussbaum D, Prussick R. Psoriasis and Psychological Comorbidities.

J Psoriasis and Psoriatic Arthritis. 2016;1(2):80-85.

Prussick R, Unnebrink K, Valdecantos WC. Efficacy of Adalimumab Compared with

Methotrexate or Placebo Stratified by Baseline BMI in a Randomized Placebo-Controlled Trial

in Patients with Psoriasis. J Drugs Dermatol. 2015;14 (7):611-615.

Naik H, Natarajan B, Stansky E, Ahlman M, Teague H, Salahuddin T, Ng Q, Krishnamoorthy P,

Dave J, Rose S, Doveikis J, Playford M, Prussick R, Ehrlich A, Kaplan M, Lockshin B, Gelfand

J, Mehta N. Severity of Psoriasis Associates with Aortic Vascular Inflammation Detected by

FDG PET/CT and Neutrophil Activation in a Prospective Observational Study. Arterioscler

Thromb Vasc Biol. 2015 Dec;35(12):2667-76.

Prussick R, Prussick L, Nussbaum D. Nonalcoholic Fatty Liver Disease and Psoriasis: What a

Dermatologist Needs to Know. J Clin Aesthet Dermatol. 2015;8(3): 43-45.

Prussick L, Prussick R. Vitamin D and Psoriasis. Practical Dermatol. 2013;10 (11):27-30.

Prussick R, Prussick L, Gutman J. Psoriasis Improvement in Patients using Glutathione-

Enhancing, Non-Denatured Whey Protein Isolate: A pilot study. J Clin Aesthet Dermatol.

2013;6(10):23-26.

Prussick R, Rengifo-Pardo M. Myelodysplastic syndrome related to the use of etanercept in a

patient with psoriasis. Psoriasis Forum. 2013;19 (1):56-57.

Prussick R, Prussick L. Biologics for Psoriasis 2013: Do we use them enough? Practical

Dermatol. 2013;10(2): 32-34.

Prussick L, Prussick R. Maintenance ultraviolet therapy in Psoriasis: Is it Necessary? Psoriasis

Forum. 2012; 18(3):147-148.

Prussick R. Biologic therapies for Psoriasis: Do we use them enough? Expert Rev Dermatol.

2010; 5(5):497-499.

Prussick R. Urticaria: An Approach to the Diagnosis and Treatment of Hives. Trauma.

1998;40(4):85-90.

Prussick R. Adverse Cutaneous Reactions to Drugs. Trauma. 1998;39(6)61-66.

Gupta AK, Sibbald RG, Lynde CW, Hull PR, Prussick R, Shear NH, De Donker P, Daniel R,

Elewski BE. Onychomycosis in children: Prevalence and treatment strategies. J Am Acad

Dermatol. 1997;36:395-402.

Gupta AK, Prussick R. and Sauder DN. Biological Response Modifiers. McDonald, CJ ed.

Immunodulatory and Cytoxic Agents in Dermatology. New York, N.Y.: Marcel-Dekker, Inc.

1997;71-123.

Prussick R, Wilson WH, Horn TD, and Turner ML. A Characteristic eruption associated with

ifosfamide, carboplatin, and etoposide chemotherapy after pretreatment with recombinant

interleukin-1a. J Am Acad Dermatol. 1996;35:705-709.

Prussick R. Adverse Cutaneous Reactions to Chemotherapeutic Agents and Cytokine Therapy.

Semin Cutaneous Med and Surg. 1996;15(4):267-276.

Prussick R, Shear NH. Dapsone Hypersensitivity Syndrome. J Am Acad Dermatol.

1996;35:346-349.

Gupta AK, Turnbull DH, Foster FS, Harasiewicz KA, Shum DT, Prussick R, Watteel GN, Hurst

LN, Sauder DN. High frequency 40-MHz ultrasound. A possible noninvasive method for the

assessment of the boundary of basal cell carcinomas. Dermatol Surg. 1996; 22(2);131-6.

Shear NH and Prussick R. Drug Eruptions and Skin Manifestations of Immune Suppression. In

Dover, J.S. ed. Cutaneous Medicine and Surgery: Self-Assessment and Review. Philadelphia,

PA: W.B. Saunders Co. 1995.

Gupta AK, Prussick R, Sibbald G. and Knowles S.R. Terbinafine in the Treatment of

Majocchi’s Granuloma. Int J Dermatol. 1995;34(7):150.

Knowles SR, Prussick R. and Shear NH. Unexpected skin reactions to systemic drugs. Med

North Amer. 1995;18(3):273-277.

Prussick R. Adverse skin reactions to chemotherapeutic agents. Contemp Dermatol.

1994;3:7-12.

Prussick R, Knowles S. and Shear N.H. Cutaneous Drug Reactions. Curr Probl Dermatol.

1994;V:I81-124.

Prussick R, Plott TR and Stanley JR. Recurrence of Pemphigus Vulgaris Associated with IL-2

Therapy. Arch Dermatol. 1994;130:890-893.

Karpati S., Amagai M, Prussick R and Stanley, J.R. Pemphigus Vulgaris Antigen is a

Desmosomal Desmoglein. Dermatol. 1994;189 (suppl 1):24-26.

Prussick R, Gupta AK, Assaad DM, Hanna WM and Sauder, D.N. Epidermolysis Bullosa

Acquisita with Features of Bullous Lupus Erythematosus. Int J Dermatol. 1994;33:192-195.

Karpati S, Amagai M, Prussick R, Cehrs K. and Stanley JR. Pemphigus Vulgaris Antigen, a

Desmoglein Type of Cadherin, is Localized within Keratinocyte Desmosomes. J Cell Biol.

1993;122:409-415.

Prussick R, Thibault A. and Turner ML. Recall of Cutaneous Toxicity from 5-Flurouracil. Arch

Dermatol. 1993;129:644-645.

Amagai M, Karpati S, Prussick R, Klaus-Kovtun V and Stanley J.R. Autoantibodies are

Pathogenic in Pemphigus Vulgaris. J Clin Invest. 1992;90:919-926.

Prussick R, Ali MAM, Rosenthal, D. and Guyatt, G. The Protective Effect of Vitamin E on the

Hemolysis associated with Dapsone Treatment in patients with Dermatitis Herpetiformis. Arch

Dermatol. 1992;128:210-213.

Prussick R and Sauder DN. Polymyositis: A Manifestation of Chronic Graft Versus Host

Disease. J Am Acad Dermatol. 1991;24:652-653.

Patel A, Prussick R and Sauder DN. Leukocytoclastic Vasculitis associated with Streptokinase. J

Am Acad Dermatol. 1991;24:652-653.

Brown GG, Bell G. and Prussick R. Variation in Animal Mitochondrial Genes and Gene

Products. Endocytobiology. Walter de Gruyer & Co.: Berlin-New York. 1983;II(246).

II. Abstracts

Amagai M, Karpati S, Prussick R, Klaus-Kovtun V and Stanley JR. Autoantibodies Against the

Cadherin-like Homophilic Binding Region of Pemphigus Vulgaris Antigen Cause Acantholysis.

J Invest Dermatol. 1992;98:566.

Prussick R, Ali MAM and Rosenthal D. Protection from Oxidative Damage by Oral Vitamin E

and Vitamin C in patients on long term Dapsone Therapy. Can Dermatol Assoc J. 1990;(4)3.

Brown GG and Prussick R. Deletion and Insertion Events in Rat Mitochondrial DNA.

Genetics. 1983;104(1:9).

III. Book Reviews

Adverse Cutaneous Reactions to Medications. By Sanford M. Goldstein MD and Bruce U.

Wintroub MD, Baltimore, 1996, Williams & Wilkins, 160 pages. J Am Acad Dermatol.

1997;37:29.

IV. Posters

Efficacy of Adalimumab Compared With Placebo Stratified by Baseline Disease Severity in

Moderate to Severe Psoriasis from the CHAMPION and REVEAL Studies. Armstrong A,

Lambert J, Prussick R, Geng Z, Reyes Servin O. AAD Annual Meeting, San Diego, CA.

February 2018.

Effect of Adalimumab Treatment on Body Weight and Metabolic Parameters: Integrated

Analysis from Phase 2/3 Clinical Trials in Patients with Moderate to Severe Psoriasis. Prussick

R, Gu Y, Reyes Servin O. EADV Congress, Vienna, Austria. September 2016 and AAD Annual

Meeting, Orlando, FL. March 2017.

Improvement in Psoriasis Skin Disease Severity is Associated with Improvement in Aortic

Vascular Inflammation by FDG PET/CT. Day A, Lerman J, Aberra T, Joshi A, Rodante J,

Kabbany M, Silverman J, Dahlya A, Natarajan B, Teague H, Salahuddin T, Ng Q, Playford M,

Gerson E, Prussick R, Ehrlich A, Lockshin B, Ahlman M, Gelfand J, Mehta N. EADV Congress,

Vienna, Austria. September 2016.

Efficacy of Adalimumab Compared with Methotrexate or Placebo Stratified by Baseline BMI in

a Randomized Placebo-Controlled Trial. Ronald Prussick MD, Kristina Unnebrink PhD, Eric

Gorayeb MD. Fall Clinical Dermatology Meeting, Las Vegas, Nevada. October 2014 and AAD

Annual Meeting, San Francisco, CA. March 2015.

ACADEMIC LECTURES/FORUMS/ROUNDTABLES/WEBINARS

“Psoriasis 101: An Overview”. Grand Rounds Internal Medicine. Grady Hospital, Atlanta, GA.

Sponsored by the National Psoriasis Foundation. March 2018.

“Comorbidities in Psoriasis: What a Dermatologist Needs to Know”. Focus Session Director.

AAD Annual Meeting. San Diego, CA. Feb 2018.

“Comorbidities in Psoriasis”. Early Careers Physician Symposium. Sponsored by the National

Psoriasis Foundation. Hershey, Pa. October 2017.

“ Every Patient Every Visit: Looking Beyond the Skin for Patients with Psoriatic Arthritis”.

Speaker Training for AbbVie Immunology. Dallas, TX. October 2017.

“A Milestone in the Treatment of Moderate to Severe Hidradenitis Suppurativa”. Product

Theater, 94th Annual Atlantic Dermatology Conference. Sponsored by AbbVie Immunology.

Toronto, Canada. May 2017.

“ Comorbidities in Psoriasis: What a Dermatologist Needs to Know”. Focus Session Director.

AAD Annual Meeting. Orlando, Fl. March 2017.

“Learning the Links: Discussing Comorbidities Associated With Plaque Psoriasis and

Hidradenitis Suppurativa”. AbbVie Speaker Training. Dallas, TX. December 2016.

“Krazy Kodachromes” for Derm In-Review Online. Educational resource to prepare for Board

Certification Exams. September 2016.

“Alternative and Complementary Treatments in Dermatology”. Guest Speaker at the 38th Annual

Bob Lester Post-Graduate Dermatology Seminar. Toronto, Canada. November 2016.

“Update on Comorbidities in Psoriatic Disease”. Guest Faculty at the 12th Annual Toronto

Psoriasis Seminar. Toronto, Canada. November 2016.

“Alternative and Complementary Treatments in Psoriasis”. AAD Summer Meeting. Boston,

MA. July 2016.

“A Milestone in the Treatment of Moderate to Severe Hidradenitis Suppurativa”. The National

Academy of Dermatology Nurse Practitioners Annual Conference”. Sponsored by AbbVie

Immunology. Clearwater, FL. May 2016.

“Comorbidities in Psoriasis: What a Dermatologist Needs to Know”. Focus Session Director.

AAD Annual Meeting. Washington, DC. March 2016.

“A Legacy in Dermatology. A Commitment to Your Patients”. Sponsored by AbbVie

Immunology. Jacksonville, FL. February 2016.

“Ustekinumab Safety Data” and “Comorbidities in Psoriasis”. Annual Speaker Training.

Sponsored by Janssen Biotech. Denver, CO. January 2016.

“Alternative Treatments in Psoriasis” Guest Faculty at the 11th Annual Toronto Psoriasis

Seminar. Toronto, Canada. September 2015.

“Comorbidities in Psoriatic Diseases”. Guest Speaker at the Canadian Dermatology and

Rheumatology Comorbidities Initiative in Psoriatic Disease. Toronto, ON, Canada, September

2015.

Webinar:“ICD-10-CM and Psoriasis Coding: What you need to know.” Ronald Prussick, MD,

FRCP(C), FAAD and Faith McNicholas. Sponsored by The National Psoriasis Foundation.

September 2015.

“Partners in Care: Collaborating to Advance the Care for Patients with Psoriatic Arthritis” .

Dermatology and Rheumatology dual slide deck. National Speaker Training webcast with Dr

Phil Mease. Sponsored by AbbVie Immunology. August 2015.

“Understanding Psoriatic Disease Comorbidities”. National NPF Volunteer Conference.

Sponsored by the National Psoriasis Foundation. San Francisco, CA. July 2015.

“Roundtable Discussions in Dermatology: Biologic Therapy in Adults with Moderate to Severe

Plaque Psoriasis or Active Psoriatic Arthritis”. Sponsored by Janssen Biotech. New York, New

York. May 2015.

“ An Oral PDE4 inhibitor for the Treatment of Moderate to Severe Plaque Psoriasis” Sponsored

by Celgene. White Plains, MD. April 2015.

“Comorbidities in Psoriasis: What a Dermatologist Needs to Know”. Focus Session Director.

AAD Annual Meeting. San Francisco, CA, March 2015.

“Efficacy of Adalimumab Compared With Methotrexate or Placebo Stratified by Baseline BMI in

a Randomized, Placebo-Controlled Trial. Poster Presentation. AAD Annual Meeting. San

Francisco, CA, March 2015.

“Panel Discussion on Frequently Asked Questions: Psoriasis Comorbidities”. Stelara National

Faculty Training. Sponsored by Janssen Biotech, Inc. Atlanta, GA, January 2015.

“Plaque Psoriasis: Clearing Skin, Challenging Expectations”. Sponsored by AbbVie

Immunology. Gainesville, FL, January 2015.

“Clinical Casebook in Dermatology: Biologic Therapy in Moderate to Severe Plaque Psoriasis

and Active Psoriatic Arthritis”. Sponsored by Janssen Biotech, Inc, Philadelphia, PA,

December 2014.

“Achieving Results: Clinical Trial Experience Translated into Clinical Practice”. Sponsored by

AbbVie Immunology, Atlanta, GA, October 2014.

“Psoriatic Arthritis: Co-Management”. Sponsored by AbbVie Immunology. Falls Church, VA,

October 2014.

National Psoriasis Foundation Corporate Roundtable at the AAD- Physicians Panel.

Denver,CO, March 2014.

Guest Dermatologist for Video on “Psoriatic Disease and Humira”. Made for Healthcasts.com

and The Clinical Advisor.com. Denver, CO, March 2014.

“Considerations for Making Therapeutic Decisions in Patients with Psoriasis”. Sponsored by

Janssen Biotech, Inc, Charlottsville, VA, October 2013.

“Safety Profile: Putting into perspective”. Sponsored by Abbvie Immunology, Pittsburgh,PA,

October 2013.

“Current Psoriasis Treatments: How to Choose”, Lecture for WHC/Georgetown Dermatology

Residents, Washington Hospital Center, Washington, DC, September 2013.

“Safety Profile: Putting it into Perspective”, Sponsored by Abbvie Immunology, Honolulu, HI,

July 2013.

“Long-Term Treatment and Retreatment of Moderate to Severe Chronic Plaque Psoriasis”.

Sponsored by Abbvie Immunology, Orlando,FL, May 2013.

“Comorbidities in Patients with Psoriasis”. Atlantic Dermatological Conference, Washington

DC, April 2013.

“Long-Term Treatment and Retreatment of Moderate to Severe Chronic Plaque Psoriasis”.

Sponsored by Abbott Immunology, Charlotte, NC, November 2012.

“Review of a Multicenter, Double-Blind Study to Treat Acne Vulgaris”. Sponsored by L’Oreal

USA, Inc., Bethesda, MD, November 2012.

“Treatment Strategies for Psoriatic Disease”. Sponsored by Abbott Immunology, Annapolis,

MD, October 2012.

“Picato Gel. A New Treatment for Actinic Keratoses”. Sponsored by LEO Pharma Inc. Chevy

Chase, MD, October 2012.

“Safety Data for Humira in Moderate to Severe Plaque Psoriasis”. Sponsored by Abbott

Immunology, Atlanta, GA, July 2012.

“Dysport and Restylane training”. Sponsored by Medicis Inc., Bethesda, MD, June 2012.

“A Global Clinical Trial Safety Review”. Sponsored by Abbott Immunology, Charlottsville,VA,

May 2012.

“Treatment Strategies for Psoriatic Diseases”. Sponsored by Abbott Immunology, Baltimore,

MD, May 2012.

“Long term Treatment and Retreatment of Moderate to Severe Chronic Plaque Psoriasis”.

Sponsored by Abbott Immunology, Atlanta, GA, February 2012.

“Managing Moderate to Severe Psoriasis in Patients Ready for a Biologic”. Sponsored by

Abbott Immunology, Lynchburg, VA, February 2012.

“Psoriasis: A Closer Look. A Program for Primary Care Providers”. Sponsored by Abbott

Immunology, Rockville, MD, October 2011.

“A Global Trial Safety Review of Adalimumab for Gastroenterologists”. Sponsored by Abbott

Immunology, National Harbor, MD, October 2011.

“A Global Clinical Trial Safety Review”. Sponsored by Abbott Immunology, Richmond, VA,

June 2011.

“Long Term Treatment and Retreatment of Moderate to Severe Chronic Plaque Psoriasis”.

Teleconference to 5 cities in USA, Sponsored by Abbott Immunology, North Bethesda, May 2011.

“Biologic Drugs for Psoriasis- Do We Use Them Enough?” Forum Director. AAD Annual

Meeting, New Orleans, LA, February 2011.

“Comorbidities Associated With Psoriasis”, Hospital Mexico, San Jose, Costa Rica, August

2010.

“Adverse Drug Reactions of the Skin” San Jose Dermatology Meeting, San Jose, Costa Rica,

August 2010.

“Treatment of Psoriatic Diseases: A Clinical Trial Review”. Sponsored by Abbott Immunology,

Philadelphia, PA, July 2010.

“Biologic Drugs for Psoriasis-Do We Use Them Enough?”. Forum Director, AAD Annual

Meeting, Miami, FL, March 2010.

“Review of Botulinum Toxin Choices for Cosmetic Use”. Dinner Program Sponsored by

Medicis Inc., Miami, FL, March 2010.

“Biologic Treatments for Psoriasis- What Pharmacists Need To Know”. Sponsored by Abbott

Immunology, Bethesda, MD, December 2009.

“Treatment Options for Actinic Keratoses”. Sponsored by Pharmaderm. Tysons Corner, VA,

September 2009.

“Psoriasis Case Review”. Sponsored by Abbott Immunology, Chevy Chase, MD, September

2009.

“Biologic Drugs for Psoriasis - Do We Use Them Enough?”. Forum Director, AAD Annual

Meeting, San Francisco, CA, March 2009.

“Psoriasis and Psoriatic Arthritis 2009”. Scientific Congress Update, CME Program for

Primary Care. San Francisco, CA, March 2009.

“Adverse Cutaneous Reactions to Drugs”. SDPA Annual Meeting, Tampa, FL, November

2008.

“Unveiling Humira for Psoriasis”. Regional Guest Speaker, Abbott Immunology,

Baltimore/Washington, DC, Baltimore, MD. February 2008.

“Review of Biologic Agents to Treat Moderate to Severe Psoriasis”. Dermatology Residents

Lecture: Washington, D.C., Sponsored by Abbott Immunology, February 2008.

“Review of New Biologic Treatment for Psoriasis”. Thomas Jefferson University, Department

of Dermatology, Philadelphia, PA., Sponsored by Abbott Immunology, February 2008

“Update on Psoriasis Therapies”. Hahnemann University, Drexel College of Medicine,

Department of Dermatology Grand Rounds, Philadelphia, PA. Sponsored by Abbott

Immunology, February 2008.

“Psoriasis as a Systemic Inflammatory Disease”. Suburban Hospital Medical Grand Rounds,

Bethesda, MD, November 2007.

“Psoriasis: Topical Strategies for Treating Psoriasis”. Ellicott City, MD. Sponsored by Warner

Chilcott, Inc. March 2007.

“ Review of Biologic Treatments in Psoriasis”. Duke University, Department of Dermatology,

Durham, NC, sponsored by Abbott Immunology, April 2006.

“Adverse Cutaneous Reactions to Drugs”. Holy Cross Hospital Continuing Medical Education

Lecture, Silver Spring, MD, Jan 1997.

“An Approach to Hives”. Holy Cross Hospital Grand Medical Rounds, Silver Spring, MD,

Nov. 1996

“Chronic Urticaria”. Bethesda, MD, sponsored by Pfizer Inc., Oct 1996.

“Approach to Dermatology Patient Consultations”. Dermatology Teaching Rounds, National

Naval Medical Centre, Bethesda, MD, June 1996.

“Hypersensitivity Drug Reactions”. Grand Medical Rounds, Suburban Hospital, Bethesda, MD,

May 1996.

“Approach to Adverse Drug Reactions”. Grand Medical Rounds, Shady Grove Adventist

Hospital, Rockville, MD, Mar. 1996.

“Adverse Drug Reaction Forum”. American Academy of Dermatology Annual Meeting,

Washington, DC, Feb. 1996.

“Hypersensitivity Drug Reactions”. Walter Reed Hospital Teaching Lectures, Washington, DC,

Oct. 1995.

“Antimicrobial Adverse Drug Reactions”. Sponsored by the Peterborough Medical Education

Association Grand Rounds, in conjunction with Eli Lilly Canada Inc., Mar. 1995.

“Adverse Drug Reaction Forum”. AAD Annual Meeting, New Orleans, Feb. 1995.

“Macrolide Antibiotics”. Frontiers in Dermatology, Montreal, Quebec, Dec. 1994.

“Dapsone Hypersensitivity Syndrome”. Medical Grand Rounds, Sunnybrook Health Science

Centre, Toronto, Ontario, Nov. 1994.

“Adverse Drug Reactions to Antimicrobial Therapy (A Review & Update)”. Sponsored by the

Continuing Medical Education Association for Pediatricians of Waterloo, Ontario in conjunction

with Eli Lilly Canada Inc., Oct. 1994.

“Adverse Reactions to Oral Antibiotics”. Sunnybrook Health Science Centre, Department of

Family & Community Medicine, Toronto, Ontario, June 1994.

“Cutaneous Reactions to Chemotherapeutic Agents”. Dermatology Grand Rounds, Sunnybrook

Health Science Centre, Toronto, Ontario, May 1994.

“Drug Reactions Commonly Seen in Internal Medicine”. Medical Core Lecture, Department of

Medicine, Sunnybrook Health Science Centre, Toronto, Ontario, March 1994.

“A Review of Drug Eruptions”, sponsored by The Continuing Medical Education Association of

Newmarket, Ontario. Sponsored by Eli Lilly Canada Inc., Feb. 1994

“Drug Eruptions - The Ultimate Test”, Medical Grand Rounds, Sunnybrook Health Science

Centre, Toronto, Ontario, Jan. 1994.

“Adverse Drug Reaction Forum”. AAD Annual Meeting, San Francisco, Dec. 1993.

“Adverse Cutaneous Reactions to Cytokines & Chemotherapeutic Agents”, Oncology Grand

Rounds, The Bayview Regional Cancer Centre, Toronto, Ontario, Nov. 1993.

“Infestations of the Skin”, Medical Grand Rounds, Peel Memorial Hospital, Brampton, Ontario,

May 1993.

“Vascular Lesions in Childhood”, Pediatric Grand Rounds, North York General Hospital,

Willowdale, Ontario, Feb. 1993.

“Pregnancy Eruptions”, Continuing Medical Education Symposium on Treatment of Common

Dermatological Problems For the Family Practitioner, University of Toronto, Jan. 1993.

“Adverse Drug Reaction Forum”, AAD Annual Meeting, San Francisco, Dec. 1992.

“Vascular Lesions in Childhood”, Walter Reed Hospital Teaching Lectures, Washington, D.C.

Sept. 1992.

“The Protective Effect of Vitamin E on the Hemolysis associated with Dapsone Treatment in

Patients with Dermatitis Herpetiformis”, AAD Annual Meeting, Residents and Fellows

Symposium, December 1990 (Atlanta) and the John Cole Memorial Residents Competition

(Toronto), Feb. 1991.

“The Pustular Dermatoses in Pregnancy”, AAD Annual Meeting, December 1990(Atlanta) &

the John Cole Memorial Residents Competition (Toronto), Feb. 1990.

PUBLIC/PREVENTATIVE MEDICINE – LECTURES, INTERVIEWS & ARTICLES

“Psoriasis Comorbidities: Updates”. Interviews on Dermtube. March 2015, 2016 and 2018.

“Be Joint Smart”. Webinar on the benefits of early diagnosis, treatment and life style changes

that can help with psoriatic arthritis. Given with Dr. Evan Siegel, Rheumatologist. Sponsored

by the National Psoriasis Foundation. November 2017.

“More Than Skin Deep: Targets, Treatments & What it Means for You”. Bethesda, MD,

Sponsored by the National Psoriasis Foundation. June 2017.

“ Nail Psoriasis Patient Education Webinar”. Sponsored by the National Psoriasis Foundation.

June 2017.

“Eczema prevention: Avoid the triggers”. WebMD video interview. July 2016.

“ELLASENSE- A novel anti-aging skin care line with SynerG-4”. Presented at the Immunotec

Annual Conference. Las Vegas, Nevada. February 2016.

“More Than Skin Deep: Triggers, Treatments and You”. Sponsored by the National Psoriasis

Foundation. Bethesda, MD. June 2015.

“Ronald B. Prussick, MD: Interviewed on the topic of Communication in Patients with

Psoriasis” in the Physician Focus Section. Practical Dermatology. 2014;11(10):82.

“Psoriasis Treatments: How Biologics Work”. Everyday Health.com. December 2013.

“Be Joint Smart”, Outreach program co-sponsored by the National Psoriasis and Arthritis

Foundations. Shady Grove Adventist Hospital, Rockville, MD, October 2012.

“Melanoma Prevention and Awareness”, Healthcentral.com, June 2012.

“Psoriasis Triggers and Management”, Healthcentral.com. October 2011.

“Psoriasis: More Than Skin Deep” Sponsored by the National Psoriasis Foundation. Marriott

Hotel, Washington, DC, July 2011.

“If I had Severe Psoriasis and my Doctor Recommended Biologic Drugs“,www.medlineplus.gov

and www.insidermedicine.com . March 2009.

“Acne Treatment”, FOX 5 News Medical Report, February 2007.

“Excimer Laser for Psoriasis”, NBC News Medical Report, May 2006.

“Skin Cancer: Detection, Prevention & Treatment”, Potomac Rotary Club, MD, Mar. 1997.

“Aging Skin”, Potomac Seniors Club, Potomac MD, Feb. 1997.

“Skin Cancer: Detection, Prevention & Treatment”, Public Lecture, Maplewood Senior Center,

Bethesda, MD, Feb. 1997.

“Skin Care: Protection & Treatment”, Daytime Report: News Channel 8, Virginia, Jan. 1997.

“Skin Cancer: Detection, Prevention & Treatment”, Public Lecture, Ring House, Rockville,

MD, Dec. 1996.

“Skin Cancer: Dectection & Prevention”, Magruder High School, Montgomery County Public

Schools Connection Resource Bank, Oct. 1996.

“Skin Cancer: Detection, Prevention & Treatment”, Public Lecture, Holiday Park Multiservice

Senior Center, Wheaton, MD, Sept. 1996.

“Skin Care”, Suburban Hospital Pavillion, Bethesda, MD, July 1996.

“Fry Now, Pay Later”, article published in Women Today, Rockville, MD, June 1996.

“Skin Cancer Detection & Prevention”, Public Lecture, OASIS (Older Adult Service &

Information System) Chevy Chase, MD, May 1996.

“The Treatment of Acne Scarring”, Montgomery Gazette, March 1996.

“Laser Treatment for the Skin”, Public Lecture, Holiday Park Multiservice Senior Center,

Wheaton, MD, Oct 1995.

“Have You Put Away Your Sunscreen?”, Montgomery Gazette, Maryland, Sept. 1995.

“Treatment of Sun-Damaged Skin”, Montgomery Gazette, Maryland, Sept. 1995

CLINICAL STUDIES & RESEARCH ACTIVITIES

A 52-week multicenter, randomized, double-blind study of secukinumab to demonstrate efficacy

as assessed by PASI and Investigator ‘s Global Assessment after 12 weeks of treatment,

compared to ustekinumab, and to assess long-term safety, tolerability and efficacy in subjects

with moderate to severe plaque psoriasis (CLARITY). Ongoing.

NPF-CORRONA Psoriasis Registry. Investigator. July 2015-ongoing.

Glutathione Supplementation in Plaque Psoriasis, (Immunotec, Inc.). Principal Investigator.

2011.

Observe 5 safety surveillance study utilizing Etanercept to treat Psoriasis, (Amgen Inc.), October

2006-2011.

Gene Expression Analysis of Human Skin Samples,Before and After Systemic Treatment

Intervention in Psoriasis, (Gene Logic Inc.). Principle Investigator. November 2003- April 2009.

Jet Trial: Juvederm Experience Trial. A Clinical Evaluation of Juvederm Ultra Injectable Gel for

the Correction of Moderate to Severe Facial Wrinkles and Folds. (Allergan, Inc.), November

2006 - June 2007.

A Phase IV, Open label, multicenter prospective study to evaluate the safety and efficacy of the

use of Solaraze Gel in the treatment of AK lesions post Cryosurgery (Doak Dermatologics) June

2006- November 2006.

Clobex spray community based research assessment trial to evaluate the efficacy, tolerance to

treatment, and subject satisfaction with Clobex (clobetasol propionate) spray 0.05% as

monotherapy or add-on therapy to existing systemic/topical agents in the treatment of moderate

to severe plaque psoriasis. COBRA (Galderma Inc.) 2006.

Raptiva Epidemiologic study of Psoriasis outcomes and safety events in patients with chronic,

moderate to severe plaque psoriasis. RESPONSE TRIAL (Genentech Inc.) 2005-2009.

A Phase IIIB, Open label, multicenter prospective study to evaluate the safety of subjects with

Psoriasis treated with Etanercept [Enbrel] (Amgen Inc.) 2004.

A Phase IIIB, Open Label effectiveness and safety study of topical Imiquimod [Aldara]5%

cream in the treatment of Actinic Keratosis (3M Inc.) 2004.

A Phase IIIB, Open Label, multicenter study to evaluate the safety of subcutaneously

administered Efalizumab [Raptiva] in moderate to severe Psoriasis (Genentech Inc.) 2003-2004.

Analysis of Gene Expression of Human Skin Samples through Disease Progression in Psoriasis

(Gene Logic Inc.). Principle Investigator, 2002-2005.

Analysis of Gene Expression of Human Skin Samples through Gene Expression in Atopic

Dermatitis (Gene Logic Inc.). Principle Investigator, 2003-2004.

A dose determination study comparing two different concentrations (0.3% and 1.0%) and two

application frequencies of Clindamycin cream and its vehicle in the treatment of subjects with

moderate to severe Rosacea (Dow Pharmaceuticals Inc.), 1999.

The safety and efficacy of Clindagel QD versus Vehicle QD in subjects with mild to moderate

Acne Vulgaris (Galderma Inc.), 1999.

Phase I study of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory

metastatic cancer (Associate Investigator, National Institutes of Health), 1997.

Comparative effects of Fusidic acid (2%) lotion and Erythromycin (2%) solution in the treatment

of acne vulgaris of the face (Leo Laboratories), Sept. 1994-Dec. 1994.

Double-blind randomized study to compare Lipocort C (clobetasol proprionate liposome cream

0.025%) versus clobetasol proprionate cream 0.05% in psoriasis (Lipopharm Inc.), 1993-94.

A multi-controlled double blind placebo controlled evaluation of topical 3% diclofenac in 2.5%

hyaluronic acid in the treatment of superficial basal cell carcinoma (Hyal Pharmaceutical Corp.),

June 1993-Dec. 1993.

Open study to compare EMLA patch versus EMLA 5% cream for analgesia prior to skin surgery

(ASTRA Pharm. Inc.), June 1993-Dec.1993.

Double-blind randomized study to compare the efficacy of Famciclovir and Acyclovir versus

Acyclovir alone in herpes zoster (Smith-Kline Beecham Inc.), Jan-June 1993.

Double-blind, randomized dose-ranging study to assess the efficacy of Famciclovir in genital

herpes (Smith-Kline Beecham Pharma Inc.), Jan-June 1993.

Laboratory investigation of the immunogenic epitope(s) in Pemphigus Vulgaris, National Cancer

Institute, N.I.H., July 1991-November 1992.

Clinical investigation of photodamaged skin treated with topical Ro 15-1570 (Hoffman-

LaRoche, Inc.), McMaster University (Dermatology), Jan.-July 1989.

Clinical investigation of the protective effect of Vitamin E in the hemolysis associated with

Dapsone treatment in patients with Dermatitis Herpetiformis, McMaster University

(Dermatology & Hematology), Jan.-July 1989.

Laboratory investigation of genetic control of resistance and susceptibility to experimental

cutaneous candidiasis in mice, Montreal General Hospital (Dermatology & Immunology),

McGill University, Jan.-April 1987.

VOLUNTEER AND COMMUNITY SERVICE

Honorary Medical Walk Chair, Walk To Cure Psoriasis, Washington, D.C., September 2011.

Health Volunteers Overseas, Hospital Mexico, San Jose, Costa Rica, August 2010.

McGill Alumni Association, Leadership Council, Washington, D.C.

ACADEMIC/PROFESSIONAL AWARDS

2017 “Voluntary Teacher of the Year” Award. Department of Dermatology.

George Washington University

2003-2017 “America’s Top Physicians”, Consumers’ Research Council of America

2015 “RK Schachter Lectureship” in Recognition of your contributions to the lives of

patients with psoriasis: University of Toronto

2013 “Super Doctors” Award

2011 Leadership Circle for Volunteerism, American Academy of Dermatology

2007-2017 “Best Dermatologist”, Washingtonian Magazine

1999-2016 “Top Doctors”, Washingtonian Magazine

1983 Scarlet Key, McGill University, Highest Distinction in Student Activities

1983 Muriel Roscoe Prize in Biology, McGill University

1980-83 J.W. McConnell Scholarship Award in Science, McGill University

1980-83 McGill University Scholar

March 2018